publication date: Jul. 24, 2020

In Brief

Edward Chu named director of Albert Einstein Cancer Center, VP for cancer medicine at Montefiore Medicine

Edward Chu was named director of Albert Einstein Cancer Center, vice president for cancer medicine at Montefiore Medicine, professor of medicine and of molecular pharmacology, and will hold the Carol and Roger Einiger Professorship of Cancer Medicine at Einstein.

The institution holds an NCI Cancer Center designation.

The appointment will be effective Oct. 1.

David Goldman was the previous director of the cancer center.

Chu is the deputy director of the University of Pittsburgh Medical Center’s Hillman Cancer Center, co-leader of the HCC Cancer Therapeutics Program, director of the HCC Phase I Program, as well as the associate director of the University of Pittsburgh Drug Discovery Institute and chief of the Division of Hematology-Oncology.

Chu is a NIH-funded basic, translational, and clinical investigator, and clinical oncologist, with a long history of developing and leading phase I and phase II clinical trials, particularly for colorectal cancer and other gastroenterology cancers.

Chu has been active in designing and developing novel agents and treatment approaches. His research has also focused on the molecular mechanisms underlying drug resistance. Additionally, he has studied Chinese herbal medicine and its integration with standard care with the goal of improving outcomes and reducing the toxic side effects of chemotherapy.

AECC works with the Montefiore Einstein Center for Cancer Care to conduct clinical trials. They treat residents of the Bronx and Hudson Valley. Approximately 80% of its clinical trial participants are racial or ethnic minorities, and it is one of only 14 minority/underserved clinical sites designated by the NCI Community Research Program.

 

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.